


PIPELINE



^aPrior treatment with 3 or more kinase inhibitors, including imatinib.
^bTGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
^cTirabrutinib is under license agreement with ONO PHARMA to Deciphera Pharmaceuticals, LLC.
^dSapablursen is under license agreement from Ionis Pharmaceuticals to ONO PHARMA and its affiliates.
1L, first line; 2L, second line; ASO, antisense oligonucleotide; BTK, Bruton tyrosine kinase; CD3, cluster of differentiation 3; cGVHD, chronic graft-versus-host disease; CRPC, castration-resistant prostate cancer; CSF1R, colony-stimulating factor 1 receptor; EP4, prostaglandin E receptor 4; GCN2, general control nonderepressible 2; GIST, gastrointestinal stromal tumor; *KIT*, receptor tyrosine kinase type III; PD-1, programmed cell death protein 1; PDGFRA, platelet-derived growth factor receptor alpha; RCC, renal cell carcinoma; R/R, relapsing or refractory; S1P5, sphingosine-1-phosphate receptor 5; TGCT, tenosynovial giant cell tumor; TKI, tyrosine kinase inhibitor; TMPRSS6, transmembrane protease serine 6; ULK, Unc-51-like autophagy activating kinase.
©2025 Deciphera Pharmaceuticals, LLC, a member of ONO PHARMA. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: Deciphera and the Deciphera logo. All Rights Reserved. 11/2025 DCPH-M00912